151 related articles for article (PubMed ID: 34728807)
21. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
23. RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST.
Sun D; Haddad R; Kraniak JM; Horne SD; Tainsky MA
Mol Cancer Res; 2013 Jun; 11(6):616-27. PubMed ID: 23423222
[TBL] [Abstract][Full Text] [Related]
24. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.
Keng VW; Rahrmann EP; Watson AL; Tschida BR; Moertel CL; Jessen WJ; Rizvi TA; Collins MH; Ratner N; Largaespada DA
Cancer Res; 2012 Jul; 72(13):3405-13. PubMed ID: 22700876
[TBL] [Abstract][Full Text] [Related]
25. Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.
Innocenti F; Ou FS; Qu X; Zemla TJ; Niedzwiecki D; Tam R; Mahajan S; Goldberg RM; Bertagnolli MM; Blanke CD; Sanoff H; Atkins J; Polite B; Venook AP; Lenz HJ; Kabbarah O
J Clin Oncol; 2019 May; 37(14):1217-1227. PubMed ID: 30865548
[TBL] [Abstract][Full Text] [Related]
26. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells.
Li F; Munchhof AM; White HA; Mead LE; Krier TR; Fenoglio A; Chen S; Wu X; Cai S; Yang FC; Ingram DA
Hum Mol Genet; 2006 Jun; 15(11):1921-30. PubMed ID: 16644864
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
[TBL] [Abstract][Full Text] [Related]
28. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
[TBL] [Abstract][Full Text] [Related]
29. Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.
Peltonen S; Kallionpää RA; Peltonen J
Exp Dermatol; 2017 Jul; 26(7):645-648. PubMed ID: 27622733
[TBL] [Abstract][Full Text] [Related]
30. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.
Wallace MD; Pfefferle AD; Shen L; McNairn AJ; Cerami EG; Fallon BL; Rinaldi VD; Southard TL; Perou CM; Schimenti JC
Genetics; 2012 Oct; 192(2):385-96. PubMed ID: 22851646
[TBL] [Abstract][Full Text] [Related]
31. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
32. Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Zhang W; Lv Y; Xue Y; Wu C; Yao K; Zhang C; Jin Q; Huang R; Li J; Sun Y; Su X; Jiang T; Fan X
Oncotarget; 2016 Sep; 7(37):59098-59114. PubMed ID: 27385209
[TBL] [Abstract][Full Text] [Related]
33. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
Dasgupta B; Dugan LL; Gutmann DH
J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
[TBL] [Abstract][Full Text] [Related]
34. Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness.
Fadhlullah SFB; Halim NBA; Yeo JYT; Ho RLY; Um P; Ang BT; Tang C; Ng WH; Virshup DM; Ho IAW
Oncogene; 2019 Jul; 38(27):5367-5380. PubMed ID: 30967630
[TBL] [Abstract][Full Text] [Related]
35. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
[TBL] [Abstract][Full Text] [Related]
36. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency.
See WL; Tan IL; Mukherjee J; Nicolaides T; Pieper RO
Cancer Res; 2012 Jul; 72(13):3350-9. PubMed ID: 22573716
[TBL] [Abstract][Full Text] [Related]
38. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
39. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab.
Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G
J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598
[TBL] [Abstract][Full Text] [Related]
40. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]